Treatment options for second-stage gambiense human African trypanosomiasis.
about
Overview of the Diagnostic Methods Used in the Field for Human African Trypanosomiasis: What Could Change in the Next Years?Predicting the Impact of Intervention Strategies for Sleeping Sickness in Two High-Endemicity Health Zones of the Democratic Republic of CongoPerformance of the SD BIOLINE® HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the CongoAccuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa.Cancer in the parasitic protozoans Trypanosoma brucei and Toxoplasma gondii.Targeting the parasite's DNA with methyltriazenyl purine analogs is a safe, selective, and efficacious antitrypanosomal strategySelective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis.A novel protein kinase is essential in bloodstream Trypanosoma bruceiHow can molecular diagnostics contribute to the elimination of human African trypanosomiasis?The animal trypanosomiases and their chemotherapy: a reviewTrypanosoma brucei gambiense Spliced Leader RNA Is a More Specific Marker for Cure of Human African Trypanosomiasis Than T. b. gambiense DNA.Developing imidazole analogues as potential inhibitor for Leishmania donovani trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach.Infectious diseases. Overcoming neglect of kinetoplastid diseases.Impact of the Ebola outbreak on Trypanosoma brucei gambiense infection medical activities in coastal Guinea, 2014-2015: A retrospective analysis from the Guinean national Human African Trypanosomiasis control program.A DBS method for quantitation of the new oral trypanocidal drug fexinidazole and its active metabolites.Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases.Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles.A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolismClinical and veterinary trypanocidal benzoxaboroles target CPSF3Novel lead compounds in pre-clinical development against African sleeping sickness
P2860
Q26778571-EB0803CC-99CC-4A90-A0CC-0D265598C4B0Q28555206-73AA5523-9D02-4D86-8B9E-0D9D2D7D6D5CQ33866223-F2E1FC38-ABCB-4B15-9DA8-347A9F280172Q35039193-555962E7-E0CE-46A8-BD95-ABD7BAF1BE4BQ35895770-89518DAC-43ED-4077-92F1-06BF2F707249Q36158447-888700FD-A9F9-4EDD-98C8-4439BA2E52C1Q36298245-DD5F0CCD-26B2-4BD2-B7AD-6A84D2ACB619Q37047925-2409E2EC-C9FA-4806-A7E4-1ADCB9F2B726Q38383077-DB5761ED-6508-4C63-A22B-A59587FB0F55Q38975883-25D5BFB3-122C-4EFF-87A3-43FD8D3F22F9Q39093411-DD1AF286-8298-4925-91A7-0263C105A755Q41034709-2365402B-7133-4DE3-97FF-C1BBED9BD581Q41196369-3E1C9CF7-847A-4719-A3A0-3F60617C42E8Q44106174-6D046DF5-82D3-41E8-AD3D-F6F127C33527Q46268194-9489FBDD-4BB4-49DD-B26F-EBF1E951D65EQ48506495-0C05E7BA-3C88-470D-8A29-D5E5853B5D11Q50099275-0D7E5515-EDF1-4CCB-8398-585F5B343C1AQ52689446-B72FF704-3E0B-439D-A588-4E05C1C5DEBEQ55322154-CB9800F3-7EFC-4609-ADA5-021E2A84C115Q58694598-BF312C3E-2CD7-4AE2-A7F6-29E1B056CC13Q58842203-1F438D68-A206-4740-BD93-23617DF743E8Q58842335-86A4CE11-D426-48F0-979D-2F9283D972C4
P2860
Treatment options for second-stage gambiense human African trypanosomiasis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Treatment options for second-stage gambiense human African trypanosomiasis.
@ast
Treatment options for second-stage gambiense human African trypanosomiasis.
@en
type
label
Treatment options for second-stage gambiense human African trypanosomiasis.
@ast
Treatment options for second-stage gambiense human African trypanosomiasis.
@en
prefLabel
Treatment options for second-stage gambiense human African trypanosomiasis.
@ast
Treatment options for second-stage gambiense human African trypanosomiasis.
@en
P2093
P2860
P921
P1476
Treatment options for second-stage gambiense human African trypanosomiasis.
@en
P2093
Gilles Eperon
Julien Potet
Manica Balasegaram
Olaf Valverde
P2860
P304
P356
10.1586/14787210.2014.959496
P5008
P577
2014-09-10T00:00:00Z
2014-11-01T00:00:00Z